The endocannabinoid system and its therapeutic exploitation
The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The obvious implications are that cannabinoids and similarly acting drugs may regulate cognitive functions, modulate food intake, affect both female and male reproduction, provide neuroprotection and be involved in neurodegenerative diseases; pathophysiology of shock; inhibition of fertilized oocyte implantation; inhibition of cancer growth, angiogenesis and metastasis (for a review see ref. 71).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [71]
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“∆(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The serendipitous cloning in 1990 of the first of such proteins, the CB 1 receptor, came from the screening of an 'orphan' G-protein-coupled receptor (GPCR) with several possible ligand”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“1 ), led to the identification of plasma membrane CANNABINOID RECEPTORS in 1988 (Ref”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Functions of the endocannabinoid system The components ( Figs 3 , 4 ) and possible physiological functions of the endocannabinoid system have been extensively reviewed in recent article”
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Research works printed but not linked: 4
- Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
- Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
- Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
Cited by
Items 601–700 of 1,001
Clinical service desires of medical cannabis patients
Janichek, J. L., & Reiman, A. (2012) · Harm Reduction Journal · doi:10.1186/1477-7517-9-12 · Cited by 20
“Cannabis may also serve as a useful therapeutic alternative for individuals seeking addiction and mental health symptom management [14-16].”
BackgroundPiccolo, M., Claussen, M. C., Bluemel, S., Schumacher, S., Cronin, A., Fried, M., Goetze, O., Martin-Söelch, C., & Milos, G. F. (2019) · European Eating Disorders Review · doi:10.1002/erv.2709 · Cited by 20
Inhibitory neurotransmission drives endocannabinoid degradation to promote memory consolidation
Dubois, C., Fawcett‐Patel, J. M., Katzman, P. A., & Liu, S. J. (2020) · Nature Communications · doi:10.1038/s41467-020-20121-3 · Cited by 20
The impact of phyto- and endo-cannabinoids on central nervous system diseases:A review
Zhang, S., Zhang, N.-N., Guo, T., Sheen, L., Ho, C., & Bai, N. (2022) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2022.10.004 · Cited by 20
Brizzi, A., Brizzi, V., Cascio, M. G., Corelli, F., Guida, F., Ligresti, A., Maione, S., Martinelli, A., Pasquini, S., Tuccinardi, T., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8016255 · Cited by 20
Self-citationAntoniou, K., Galanopoulos, A., Vlachou, S., Kourouli, T., Nahmias, V. R., Thermos, K., Panagis, G., Daifoti, Z., Μαρσέλος, Μ., Papahatjis, D. P., et al. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00024 · Cited by 20
Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.06.021 · Cited by 20
Walker, V. J., Griffin, A. P., Hammar, D., & Hollenberg, P. F. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232553 · Cited by 20
“…disorders that exhibit altered tissue concentrations of arachidonoyl ethanolamide (AEA), one of the most ubiquitous endocannabinoids (ECB) (Alpini and Demorrow, 2009; Ashton and Smith, 2007; Bifulco et al., 2007; Di Marzo, 2008; Di Marzo et al., 2004; Lambert, 2007; Storr and Sharkey, 2007).”
BackgroundThe endocannabinoid system in cancer biology: a mini-review of mechanisms and therapeutic potential
Salum, K. C. R., Miranda, G. B. A., Dias, A. L., Carneiro, J. R. I., Bozza, P. T., da Fonseca, A. C. P., & Silva, T. (2025) · Oncology Reviews · doi:10.3389/or.2025.1573797 · Cited by 19
“Alterations in endocannabinoid signaling are associated with various pathological conditions, including neurodegenerative diseases (e.g., Alzheimer ’ s and Parkinson ’ s), chronic in fl ammation, obesity, and cancer (7).”
Endocannabinoid markers in autism spectrum disorder: A scoping review of human studies
Pol, M. D., & Kolla, N. J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114256 · Cited by 19
Identification of Small Molecules That Selectively Inhibit Diacylglycerol Lipase–α Activity
Appiah, K. K., Blat, Y., Robertson, B., Pearce, B. C., Pedicord, D. L., Gentles, R. G., Yu, X., Mseeh, F., Nguyen, N. H., Swaffield, J. C., et al. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113511111 · Cited by 19
Dore, A., Asproni, B., Scampuddu, A., Gessi, S., Murineddu, G., Cichero, E., Fossa, P., Merighi, S., Bencivenni, S., & Pinna, G. A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.08.055 · Cited by 19
Cannabinoid Receptor Type 1 in the Brain Regulates the Affective Component of Visceral Pain in Mice
Bajic, D., Monory, K., Conrad, A., Maul, C., Schmid, R. M., Wotjak, C. T., & Stein‐Thoeringer, C. K. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.05.041 · Cited by 19
van Esbroeck, A. C. M., Varga, Z. V., Di, X., van Rooden, E. J., Tóth, V. É., Onódi, Z., Kuśmierczyk, M., Leszek, P., Ferdinandy, P., Hankemeier, T., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104578 · Cited by 19
Diverse role of endocannabinoid system in mammalian male reproduction
Sayed, T. S., Balasinor, N., & Nishi, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120035 · Cited by 19
Cannabinoid Receptors and Cholecystokinin in Feeding Inhibition
Alén, F., Ramírez-López, M. T., de Heras, R. G., de Fonseca, F. R., & Orío, L. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-410473-0.00007-6 · Cited by 19
Kolla, N. J., Boileau, I., & Bagby, R. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-04789-9 · Cited by 19
Jennings, J. M., McNabb, D. C., Johnson, R. M., Brady, A. C., Kim, R. H., & Dennis, D. A. (2022) · Arthroplasty Today · doi:10.1016/j.artd.2022.03.018 · Cited by 19
Ferranti, A. S., & Foster, D. J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.925792 · Cited by 15
Yuan, W., Heng, L., Ma, J., Wang, X.-Q., Qu, L.-J., Duan, L. N., Kang, J., Chen, L.-W., & Gao, G. (2013) · Brain Research · doi:10.1016/j.brainres.2013.07.047 · Cited by 19
“Many of CB1 receptor ligands have therapeutic potential in a variety of disorders including obesity, nicotine and alcohol dependence (Di Marzo et al., 2004), schizophrenia (Roser et al., 2010), depression (Shearman et al., 2003), anxiety (Porter and Felder, 2001) and cognitive impairment (Black et…”
Pathophysiology of Portal Hypertension
Morales‐Ruiz, M., Rodríguez‐Vita, J., Ribera, J., & Jiménez, W. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_144 · Cited by 19
Silva, V. L. M., Silva, A. M. S., Pinto, D. C. G. A., Jagerovic, N., Callado, L. F., Cavaleiro, J. A. S., & Elguero, J. (2007) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-007-0676-4 · Cited by 19
Ragusa, G., Gómez‐Cañas, M., Morales, P., Hurst, D. P., Deligia, F., Pazos, R., Pinna, G. A., Fernández‐Ruíz, J., Goya, P., Reggio, P. H., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.06.057 · Cited by 18
Pandey, P., Chaurasiya, N. D., Tekwani, B. L., & Doerksen, R. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.06.024 · Cited by 18
“The results reported present the scope for additional neuropharmacological actions for virodhamine and analogs, besides their interactions with cannabinoid receptor function [27,55].”
Global Fecal and Plasma Metabolic Dynamics Related to Helicobacter pylori Eradication
Yap, T. W.-C., Leow, A. H., Azmi, A. N., Callahan, D. L., Perez-Perez, G. I., Loke, M. F., Goh, K., & Vadivelu, J. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00536 · Cited by 18
“The endocannabinoid system is a vital endogenous signaling system that comprises of the cannabinoid receptors, their endogenous ligands (the endocannabinoids), and the enzymes catalyzing anabolism and catabolism of endocannabinoid (Di Marzo et al., 2004).”
BackgroundChemical Proteomic Analysis of Serine Hydrolase Activity in Niemann-Pick Type C Mouse Brain
van Rooden, E. J., van Esbroeck, A. C. M., Baggelaar, M. P., Deng, H., Florea, B. I., Marques, A. R. A., Ottenhoff, R., Boot, R. G., Overkleeft, H. S., Aerts, J. M. F. G., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00440 · Cited by 18
“The lipids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the best characterized endocannabinoids (Di Marzo et al., 2004).”
BackgroundQuantitative Lipidomic Analysis of Osteosarcoma Cell-Derived Products by UHPLC-MS/MS
Casati, S., Giannasi, C., Minoli, M., Niada, S., Ravelli, A., Angeli, I., Mergenthaler, V., Ottria, R., Ciuffreda, P., Orioli, M., et al. (2020) · Biomolecules · doi:10.3390/biom10091302 · Cited by 18
“The ECS is composed of lipid-derived ECs, their G-protein-coupled receptors (CB1 and CB2), and the enzymes responsible for their synthesis, transport, and metabolism [15].”
BackgroundMella, J., Hernández-Pino, S., Morales-Verdejo, C. A., & Pessoa-Mahana, C. D. (2014) · Molecules · doi:10.3390/molecules19032842 · Cited by 18
Pharmacological Treatment of Obesity
Yoo, S. J. (2008) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2008.23.4.223 · Cited by 18
Li, B., Chen, M., Guo, L., Yun, Y., Li, G., & Sang, N. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv147 · Cited by 18
Chapter 7 Cannabinoid Receptor CB1 Antagonists
Bifulco, M., Santoro, A., Laezza, C., & Malfitano, A. M. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(09)81007-8 · Cited by 18
Self-citationRole of the endocannabinoid system in metabolic control
Wang, J., & Ueda, N. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f29071 · Cited by 17
The Endocannabinoid System: Implications in Gastrointestinal Physiology and Pathology
Caruso, E. A., Nunzio, V. D., Tutino, V., & Notarnicola, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031306 · Cited by 18
“In 1990, the first ECS receptor, CB1R, an “orphan” GPCR, was discovered [10], and then in 1993, the second endocannabinoid receptor, CB2R, located mainly on blood cells and immune tissues, was characterized [11].”
Makwana, R., Molleman, A., & Parsons, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00717.x · Cited by 17
“Endocannabinoids, including AEA and 2-AG, are known not to be stored in vesicles in nerves following synthesis, but are synthesized and released on-demand in response to nerve stimuli (Di marzo et al., 2004).”
BackgroundBragança, V. A. N., de França, T. G., de Jesus, A. C. S. P. S., Palheta, I. C., Melo, F. P. A., das Neves, P. A. P. F. G., Lima, A. H., & Borges, R. S. (2020) · Chemical Data Collections · doi:10.1016/j.cdc.2020.100345 · Cited by 17
Favero, G. R., Pereira, G. V. D. M., de Carvalho, J. C., Neto, D. P. D. C., & Soccol, C. R. (2022) · Fermentation · doi:10.3390/fermentation8020084 · Cited by 17
Management of type 2 diabetes in the obese patient: current concerns and emerging therapies
Krentz, A. J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x219661 · Cited by 17
Pisanu, C., Congiu, D., Costa, M. F., Sestu, M., Chillotti, C., Ardau, R., Deiana, V., Manchia, M., Squassina, A., & Zompo, M. D. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.09.025 · Cited by 17
“This system consists of the receptors CB1 and CB2, their ligands and the enzymes responsible for the biosynthesis (N-acyl phosphatidylethanolamine phospholipase D: NAPE-PLD) and inactivation (fatty acid amide hydrolase: FAAH) of cannabinoids (Di Marzo et al., 2004).”
Filip, R., Desrochers, G. F., Lefebvre, D. M., Reed, A., Singaravelu, R., Cravatt, B. F., & Pezacki, J. P. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.009 · Cited by 17
Rang, H. P., Dale, M. M., Ritter, J., & Flower, R. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-06911-6.50020-7 · Cited by 17
Blockade of β-cell KATP channels by the endocannabinoid, 2-arachidonoylglycerol
Spivak, C. E., Kim, W., Liu, Q., Lupica, C. R., & Doyle, M. E. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.042 · Cited by 17
“[1] Actions of the two major ECs, 2-arachidonoylglycerol (2-AG) and anandamide (AEA), are primarily mediated by two specific G protein-coupled receptors, the cannabinoid 1 and cannabinoid 2 receptors (CB1R and CB2R respectively).[2,3] The activity of the enzymes catalyzing the final steps of EC synthesis, diacylglycer…”
BackgroundDiscovery of a novel class of selective human CB1 inverse agonists
Foloppe, N., Allen, N. H., Bentley, C. H., Brooks, T., Kennett, G. A., Knight, A. R., Leonardi, S., Misra, A., Monck, N. J. T., & Sellwood, D. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.133 · Cited by 17
Roth, M. D. (2005) · Nature · doi:10.1038/434708a · Cited by 17
Pacher, P., & Ungvari, Z. I. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00020.2008 · Cited by 17
“) similar to those of cannabis via the activation of two main G protein-coupled cannabinoid receptors: CB1 and CB2 receptors (7, 9, 13, 17, 20).”
BackgroundLingegowda, H., Miller, J. E., McCallion, A., Childs, T. J., Lessey, B. A., Koti, M., & Tayade, C. (2021) · F&S Science · doi:10.1016/j.xfss.2021.09.005 · Cited by 16
Hentsch, A., Guberman, M., Radetzki, S., Kaushik, S., Huizenga, M. C. W., He, Y., Contzen, J., Kuhn, B., Benz, J., Schippers, M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c15223 · Cited by 16
Winstone, J., Shafique, H. S., Clemmer, M. E., Mackie, K., & Wager‐Miller, J. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0025 · Cited by 16
Comparative effects of chlorpyrifos in wild type and cannabinoid Cb1 receptor knockout mice
Baireddy, P., Liu, J., Hinsdale, M. E., & Pope, C. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.05.018 · Cited by 16
“Anandamide is synthesized from N-arachidonoyl phosphatidyl ethanolamine by the enzyme, N-acyltransferase phosphatidyl ethanolaminephospholipase D (Freund et al, 2003; Di Marzo et al, 2004; Pertwee, 2005).”
Silva, V. L. M., Silva, A. M. S., Pinto, D. C. G. A., Rodríguez, P. Á., Gómez‐Ruíz, M., Jagerovic, N., Callado, L. F., Cavaleiro, J. A. S., Elguero, J., & Fernández‐Ruíz, J. (2010) · ARKIVOC · doi:10.3998/ark.5550190.0011.a19 · Cited by 16
Tutino, V., Nunzio, V. D., Tafaro, A., Bianco, G., Gigante, I., Scavo, M. P., D’Alessandro, R., Refolo, M. G., Messa, C., Caruso, M. G., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12752 · Cited by 16
Cannabidiol Products: Review of the Regulatory and Clinical Considerations
Hawes, E. M., Lee, C. R., Brackney, D. E., Ensley, T. G., Kidd, J., & Page, C. P. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.07.022 · Cited by 17
Lopresti, B. J., Royse, S. K., Mathis, C. A., Tollefson, S., & Narendran, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15615 · Cited by 16
Antineoplastic and apoptotic effects of cannabinoids. N-acylethanolamines: protectors or killers?
Pushkarev, V. M., Ковзун, О. І., & Tronko, M. D. (2008) · PubMed · Cited by 16
Inhibitors of cannabinoid receptors and glucose metabolism
Scheen, A. J., & Paquot, N. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3282fcea11 · Cited by 16
Milewicz, A., Tworowska-Bardzińska, U., Jędrzejuk, D., Lwow, F., Dunajska, K., Łaczmański, Ł., & Pawlak, M. (2009) · Nature Precedings · doi:10.1038/ijo.2010.145 · Cited by 16
“The endocannabinoid system comprises two cannabinoid receptor subtypes, CB1 and CB2, their endogenous ligands and the enzymes for ligand biosynthesis and degradation (2).”
BackgroundNielsen, S. S. R., Pedersen, J. A. Z., Sharma, N., Wasehuus, P. K., Hansen, M. S., Møller, A. M. J., Borggaard, X. G., Rauch, A., Frost, M., Søndergaard, T. E., et al. (2024) · Bone · doi:10.1016/j.bone.2024.117035 · Cited by 15
The Anticancer Activity of Cannabinol (CBN) and Cannabigerol (CBG) on Acute Myeloid Leukemia Cells
Kadriya, A., Forbes-Robertson, S., & Falah, M. (2024) · Molecules · doi:10.3390/molecules29245970 · Cited by 15
cnrip1 is a regulator of eye and neural development in X enopus laevis
Zheng, X., Suzuki, T., Takahashi, C., Nishida, E., & Kusakabe, M. (2015) · Genes to Cells · doi:10.1111/gtc.12225 · Cited by 15
Unidirectional opioid-cannabinoid cross-tolerance in the modulation of social play behavior in rats
Schiavi, S., Manduca, A., Segatto, M., Campolongo, P., Pallottini, V., Vanderschuren, L. J. M. J., & Trezza, V. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05226-y · Cited by 15
Hepatic Cannabinoid Signaling in the Regulation of Alcohol-Associated Liver Disease
Yang, K.-M., Choi, S.-E., & Jeong, W. (2021) · Alcohol research : current reviews · doi:10.35946/arcr.v41.1.12 · Cited by 13
“For instance, CB1R and its ligands have critical roles in the pathogenesis of chronic liver diseases, such as steatosis and liver fibrosis.(14,15) Meanwhile, CB2R is mainly distributed in immune cells or hematopoietic organs, where it functions as a protective responder to specific pathological conditions, especially…”
BackgroundInfluentialDendritic Cell Regulation by Cannabinoid-Based Drugs
Svensson, M., Chen, P., & Hammarfjord, O. (2010) · Pharmaceuticals · doi:10.3390/ph3082733 · Cited by 15
“neuropathology, and chronic inflammatory bowel disease [71,73-76] (Table 2).”
BackgroundIslet Cannabinoid Receptors: Cellular Distribution and Biological Function
Flores, L. E., Alzugaray, M. E., Cubilla, M. A., Raschia, M. A., Zotto, H. H. D., Román, C. L., Suburo, Á. M., & Gagliardino, J. J. (2013) · Pancreas · doi:10.1097/mpa.0b013e31828fd32d · Cited by 15
Fatty Acids, Gut Microbiota, and the Genesis of Obesity
de Velasco, P. C., Ferreira, A. R. D. C., Crovesy, L., Marine, T., & do Carmo, M. D. G. T. (2018) · IntechOpen eBooks · doi:10.5772/intechopen.80664 · Cited by 15
Chapter 19 Use of Cannabinoids as a Novel Therapeutic Modality Against Autoimmune Hepatitis
Pandey, R., Hegde, V. L., Singh, N. P., Hofseth, L. J., Singh, U., Ray, S. K., Nagarkatti, M., & Nagarkatti, P. S. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(09)81019-4 · Cited by 15
Morera‐Herreras, T., Ruíz-Ortega, J. Á., Linazasoro, G., & Ugedo, L. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2043-0 · Cited by 15
“Therefore, it has been suggested that cannabinoid modulation may represent an effective tool to be included in novel therapeutic treatments of motor disturbances (Consroe 1998; Di Marzo et al. 2004; Brotchie 2003; Pacher et al. 2006).”
Scala, C. D., Mazzarino, M., Yahi, N., Varini, K., Garmy, N., Fantini, J., & Chahinian, H. (2017) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2017.04.001 · Cited by 15
Geiger, S. S., Nickl, K., Schneider, E. H., Seifert, R., & Heilmann, J. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0534-5 · Cited by 15
“Ligands of cannabinoid receptors are of high therapeutic interest since the endocannabinoid (EC) system is involved in the regulation of several biological functions such as immune regulation, memory, movement, appetite, and pain (De Petrocellis et al. 2004; Di Marzo et al. 2004 ).”
BackgroundConformationally constrained analogues of 2-arachidonoylglycerol
Vadivel, S. K., Vardarajan, S., Duclos, R. I., Wood, J. T., Guo, Z., & Makriyannis, A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.064 · Cited by 15
Jensen, M. D. (2006) · Obesity · doi:10.1038/oby.2006.294 · Cited by 15
Endocannabinoids and their receptors modulate endometriosis pathogenesis and immune response
Tayade, C., Lingegowda, H., Wei, Y., Wei, Y., Yolmo, P., Sisnett, D. J., McCallion, A., & Koti, M. (2024) · eLife · doi:10.7554/elife.96523 · Cited by 14
Evaluating the Metabolomic Profile and Anti-Pathogenic Properties of Cannabis Species
Monyela, S., Kayoka‐Kabongo, P. N., Ngezimana, W., & Nemadodzi, L. E. (2024) · Metabolites · doi:10.3390/metabo14050253 · Cited by 14
Morel, A., Lebard, P., Dereux, A., Azuar, J., Questel, F., Bellivier, F., Marie-Claire, C., Fatseas, M., Vorspan, F., & Bloch, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.565617 · Cited by 14
“The legalization of “medical marijuana” in several parts of the United States, soon followed by other countries, has produced an exponential increase in research using different active compounds derived from the Cannabis sativa plant in various medical conditions including substance use disorders (1).”
BackgroundKaras, K. H., Baharikhoob, P., & Kolla, N. J. (2021) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2021.111357 · Cited by 14
Hu, S., Cheng, G., Zhou, H., Zhang, Q., Zhang, Q., Wang, Y., Shen, Y., Lian, C.-X., Ma, X., Zhang, Q., et al. (2022) · Molecules · doi:10.3390/molecules27030702 · Cited by 14
“Cannabis sativa has been used to relieve pain and insomnia since prehistoric Eurasia Africa [1].”
BackgroundCasida, J. E., Gulevich, A. G., Sarpong, R., & Bunnelle, E. M. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.034 · Cited by 14
Klinger, F. G., Battista, N., Felici, M. D., & Maccarrone, M. (2006) · Journal of Experimental & Clinical Assisted Reproduction · doi:10.1186/1743-1050-3-3 · Cited by 14
Reward and aversion systems of the brain as a functional unit. Basic mechanisms and functions
Michel, A., Estañol, B., Senties, H., Chiquete, E., Delgado‐García, G. R., & Castillo, G. (2015) · Salud Mental · doi:10.17711/sm.0185-3325.2015.041 · Cited by 14
Betacaryophyllene – A phytocannabinoid as potential therapeutic modality for human sepsis?
Meza, A., & Lehmann, C. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.10.025 · Cited by 14
Oliveira, C. D. C., Castor, M. G. M. E., Castor, C. G. M. E., Costa, Á. D. F., Ferreira, R. C. M., da Silva, J. F., Pelaez, J. M. N., Capettini, L. D. S. A., Lemos, V. S., Duarte, I. D. G., et al. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.02.004 · Cited by 14
Closing the Gate to the Active Site
Mei, G., Venere, A. D., Gasperi, V., Nicolai, E., Masuda, K. R., Finazzi‐Agrò, A., Cravatt, B. F., & Maccarrone, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605653200 · Cited by 14
Reduced Prevalence of Alcoholic Gastritis in Hospitalized Individuals Who Consume Cannabis
Adejumo, A., Li, J., Akanbi, O. H., Adejumo, K. L., & Bukong, T. N. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13930 · Cited by 13
Boehm, E., Droessler, L., & Amasheh, S. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100808 · Cited by 14
“effects by binding to specific cannabinoid receptors, namely cannabinoid receptor 1 (CBR-1) and cannabinoid receptor 2 (CBR-2), which are part of the endocannabinoid system [7].”
BackgroundHighly Selective Drug-Derived Fluorescent Probes for the Cannabinoid Receptor Type 1 (CB 1 R)
Mach, L., Omran, A., Bouma, J., Radetzki, S., Sykes, D. A., Guba, W., Li, X., Höffelmeyer, C., Hentsch, A., Gazzi, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00465 · Cited by 13
Cannabinoid Type 1 Receptor Gene Polymorphism and Macronutrient Intake
Caruso, M. G., Gazzerro, P., Notarnicola, M., Cisternino, A. M., Guerra, V., Misciagna, G., Laezza, C., & Bifulco, M. (2012) · Lifestyle Genomics · doi:10.1159/000343563 · Cited by 13
Self-citationSiegmund, S., Wojtalla, A., Schlosser, M., Schildberg, F. A., Knolle, P. A., Nüsing, R. M., Zimmer, A., Strassburg, C. P., & Singer, M. V. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.083 · Cited by 13
“food intake, emotions, pain perception, or sleep [14].”
BackgroundIn silico gene expression profiling in Cannabis sativa
Massimino, L. (2017) · F1000Research · doi:10.12688/f1000research.10631.1 · Cited by 13
Cannabidiol effects on prepulse inhibition in nonhuman primates
Saletti, P. G., & Tomaz, C. A. B. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0101 · Cited by 13
Shah, M. A., Haris, M. N., Faheem, H. I., Hamid, A., Yousaf, R., Rasul, A., Shah, G. M., Khalil, A. A. K., Wahab, A., Khan, H. Z., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220628123224 · Cited by 14
Fowler, C. J., & Tiger, G. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.01.016 · Cited by 13
Laricchiuta, D., Musella, A., Rossi, S., & Centonze, D. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00183 · Cited by 13
“endocannabinoid and dopaminergic systems on salient stimuli”
BackgroundTomlinson, L., Tirmenstein, M. A., Janovitz, E. B., Araníbar, N., Ott, K., Kozlosky, J. C., Patrone, L. M., Achanzar, W. E., Augustine, K. A., Brannen, K. C., et al. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs217 · Cited by 13
Endocannabinoids signaling Molecular mechanisms of liver regulation and diseases
Tang, W.-X. (2016) · Frontiers in bioscience · doi:10.2741/4468 · Cited by 13
“In these receptors, seven transmembrane helices interact to form a central core that binds to the ligands (13).”
BackgroundAlmeida, R. T., Romero, T. R. L., Castor, M. G. M. E., Galdino, G., Perez, A. C., & Duarte, I. D. G. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.07.004 · Cited by 13
[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Ducobu, J., & Sternon, J. (2005) · Revue Medicale de Bruxelles · Cited by 13
Svensson, A. C., Johansson, M., Persson, E., Carchenilla, M. S. C., & Jacobsson, S. O. P. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20792 · Cited by 13
“The therapeutic usefulness of cannabinoid drugs on stroke, psychiatric disorders, multiple sclerosis, neuropathic pain, nausea, vomiting, and obesity, are under investigation (Piomelli et al., 2000; Di Marzo et al., 2004).”
BackgroundBifulco, M., Laezza, C., & Malfitano, A. M. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506071303 · Cited by 13
“In particular, cannabidiol and the cannabinoic acids seem to be promising therapeutic tools, even though their sites of action are still not well understood [1].”
BackgroundSelf-citationThe role of the endocannabinoid system in islet biology
Doyle, M. E. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32834455a8 · Cited by 13
Naderi, N., Shafieirad, E., Lakpoor, D., Rahimi, A., & Mousavi, Z. (2015) · PubMed Central · Cited by 13
Chemical Proteomics Reveals Off-Targets of the Anandamide Reuptake Inhibitor WOBE437
Gagestein, B., Stevens, A. F., Fazio, D., Florea, B. I., van der Wel, T., Bakker, A. T., Fezza, F., den Dulk, H., Overkleeft, H. S., Maccarrone, M., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00122 · Cited by 12
Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy
El-Azab, M. F., Wakiel, A. E., Nafea, Y. K., & Youssef, M. E. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i5.387 · Cited by 12
Metadata
- Authors
- Marzo, V. D., Bifulco, M., & Petrocellis, L. D.
- Affiliations
- Istituto di Chimica Biomolecolare (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- University of Salerno (IT)
- Corresponding author
- Marzo, Vincenzo Di
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 771-784
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087674201
- Cited by
- 1,090
- References
- 161
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 61 · 2023: 48 · 2022: 43 · 2021: 44 · 2020: 49 · 2019: 43 · 2018: 35 · 2017: 41 · 2016: 28 · 2015: 42 · 2014: 38 · 2013: 48 · 2012: 42
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- endocannabinoid system, cannabinoid receptors, cannabinoid therapeutics, drug development, pathological conditions
- MeSH terms
- Animals, Cannabinoids, Cannabis, Clinical Trials as Topic, Enzymes, Humans, Drug Design, Signal Transduction, Receptors, Cannabinoid, Cannabinoid Receptor Modulators, Cannabinoid Receptor Agonists, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.